The My-T study: Patient satisfaction and preference comparing topical and nasal testosterone therapies


  • Jay Lee Department of Surgery, Division of Urology, University of Calgary, Calgary, AB.
  • Gerald Brock Department of Surgery, Division of Urology, St. Joseph's Health Care, London, ON
  • Jack Barkin Department of Surgery, University of Toronto, Humber River Regional Hospital, Toronto, ON
  • Nathan Bryson Acerus Pharmaceuticals Corporation
  • Matthew A. Gronski Acerus Pharmaceuticals Corporation
  • Ross Ormsby Acerus Pharmaceuticals Corporation



Hypogonadisim, testosterone, testosterone nasal gel, titration, symptoms, patient preference, patient satisfaction, convenience


Introduction: Natesto®, testosterone nasal gel (TNG) is an intranasal testosterone therapy (TTh) used to restore testosterone levels and improve symptoms of hypogonadism. Treatment requires application two (bid) or three (tid) times daily. The Treatment Satisfaction Questionnaire for Medication (TSQM) and a Patient Preference and Use (PPU) questionnaire were used to obtain patient feedback on the use of TNG and compare it to experience with topical TTh.

Methods: The study enrolled 24 TTh-naive (TThN) and 93 TThexperienced (TThE) hypogonadal men. Treatment lasted up to 120 days, with titration at day 90 to determine the most appropriate dose for restoration of testosterone levels (11 mg bid or tid). Patient satisfaction and symptom changes were measured at days 0, 30, 60, 90, and 120. The PPU questionnaire was performed at study entry and study completion.

Results: Symptoms improved from baseline (30.6) to day 90 (35.1) (p<0.0001; +15%), consistent with testosterone replacement. TNG increased scores for effectiveness (+20%), convenience (+30%), and global satisfaction (+3%) as compared to their previous topical TTh. TThE patients reported ease of use, convenience, efficacy/ effectiveness, and travel friendliness as “likes” of TNG therapy. Overall, 67.2% of patients agreed or strongly agreed that they preferred TNG over topical TTh and 59% sought a prescription to continue treatment with TNG.

Conclusions: Patients switching from topical TTh to TNG reported significant improvements in symptoms and patient satisfaction compared to their previous topical TTh. Patients also reported a significant improvement in convenience with TNG despite two to three times daily application. Preference, satisfaction, and convenience may translate to better treatment compliance.


Download data is not yet available.



How to Cite

Lee, J., Brock, G., Barkin, J., Bryson, N., Gronski, M. A., & Ormsby, R. (2019). The My-T study: Patient satisfaction and preference comparing topical and nasal testosterone therapies. Canadian Urological Association Journal, 13(12), 384–9.



Original Research